Company news
Sona Nanotech, Inc. (CSE:SONA) news
Sona Nanotech, Inc. news releases on 6ix. Latest, Sep 11, 2026: Sona Nanotech to Present at the OTC Markets’ Life Sciences Virtual Investor Forum On September…
Press releases & updates
Sona Nanotech to Present at the OTC Markets’ Life Sciences Virtual Investor Forum On September 17th
September 11, 2026
Sona Nanotech Closes Over-Subscribed Private Placement Financing to Raise $2,527,012 in Gross Proceeds
August 10, 2026
SONA NANOTECH TO ARRANGE PRIVATE PLACEMENT FINANCING
July 31, 2026
Sona Nanotech Appoints Seasoned Biotech Commercial Executive Michael A. Fleming to Board of Directors
June 11, 2026
Sona Nanotech Announces Clinical Strategy With Two THT Combination Therapy Studies In Melanoma
May 5, 2026
Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer Conferences
April 27, 2026
Sona Nanotech Announces Appointment of Two Leading Oncologists To Its Scientific Advisory Board
April 16, 2026
Sona Nanotech Clinical Cancer Study Tissue Analysis Confirms Tumor Priming And Suggests Potential Immunotherapy Synergies
April 13, 2026
Sona Nanotech's THT Cancer Therapy Demonstrates Strong Efficacy And Durability In Combination with Immunotherapy In Peer-reviewed Preclinical Study
April 7, 2026
Sona Nanotech To Hold Investor Webinar To Discuss Follow-up Data From First-in-human Cancer Therapy Study
March 16, 2026
Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study
October 20, 2025
Sona Nanotech To Host Investor Webinar To Discuss Clinical Study
October 17, 2025
Sona Provides Update on First-In-Human Clinical Trial
August 25, 2025
Sona Announces Canadian Melanoma Clinical 'Pilot' Study Ethics Approval
July 23, 2025
First Patient Dosed in Early Feasibility Study Trial of its Cancer Therapy
July 7, 2025
Sona Announces Ethics Committee Approval For Melanoma Clinical Trial
June 27, 2025
Sona Engages Clinical Trial Clinic for First-in-Human Early Feasibility Study of its THT Cancer Therapy
June 16, 2025
Sona Successfully Completes FDA-Required Toxicity Study
May 27, 2025
Sona Announces Successful Study Showing Absence of Endotoxins In Its Cancer Therapy Gold Nanorods Prior to First-in-human Clinical Trial
May 15, 2025
BioVaxys and Sona Nanotech Enter Research Collaboration
May 7, 2025
Sona Nanotech Announces Annual Options Grants
May 1, 2025
Sona Presents Additional Preclinical Data Demonstrating Repeated Ability Of Its Cancer Therapy To Inhibit Tumor Growth In Colorectal Cancer Model
March 19, 2025
Sona Nanotech Inc. CEO David Regan to Present at the Investor Summit Virtual on March 11
March 6, 2025
Sona Nanotech Announces Filing of Provisional Patent Application
March 18, 2024
Sona Nanotech Grants Options
March 1, 2024
Sona Nanotech Announces Director Retirement
January 10, 2024
Sona Nanotech Closes Private Placement Financing to Raise $750,000 in Gross Proceeds and Announces Additional Financing
November 27, 2023
Sona Nanotech Arranges Brokered Private Placement Financing
October 18, 2023
Sona Provides Corporate Update on Operating Activities
October 12, 2023
Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study
September 11, 2023
Sona to Engage with Medical Experts and Payors to Inform Regulatory and Commercialization Strategies for Its 'THT' Cancer Therapy
September 5, 2023
Sona Nanotech "building a mountain of data" to support use of proprietary gold nanorods
June 22, 2023
New NCL Assessment of Sona's GNR Technology Highlights Process Improvement Success
June 8, 2023
Sona Nanotech Selects Minnetronix to Engineer Its Next Generation Targeted Hyperthermia Cancer Therapy Light Device
May 30, 2023
Sona Nanotech Elects New Board Chair and is Awarded Patent
May 18, 2023
Sona's Interest in Legacy Crescent Lake Lithium Property Sold to Midex Resources
May 9, 2023
Positive Results of Second Assessment of Sona's GNR Technology from U.S. Nanotechnology Characterization Laboratory
April 17, 2023
Sona Nanotech Secures Bentley Biomedical as Regulatory Affairs Advisor for its THT Colorectal Cancer Therapy Development
April 13, 2023
Sona Nanotech Closes Acquisition of Siva Therapeutics, Plans For First Therapy Application for Colorectal Cancer
March 23, 2023
Sona Nanotech Receives Waiver on Requirement to Raise Additional Equity Capital
March 6, 2023
Sona Nanotech Closes Non-Brokered Private Placement Financing to Raise $1.1M in Gross Proceeds
February 24, 2023
Sona Nanotech to Increase Size of Equity Financing
February 21, 2023
Sona Nanotech Receives Technology Assessment Results from NCL
February 8, 2023
Sona Nanotech to Acquire Cancer Therapy Developer Siva Therapeutics
January 26, 2023